Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: Evidence for tumor necrosis factor α-induced VE-cadherin cleavage

Arthritis and Rheumatism

Volumn 64, Issue 1, 2012, Pages 77-87

  Sidibé, Adama ^a,c   Mannic, Tiphaine ^a   Arboleas, Mélanie ^a   Subileau, Mariela ^a   Gulino Debrac, Danielle ^a   Bouillet, Laurence ^a   Jan, Mary ^b   Vandhuick, Thibault ^b   Le Loët, Xavier ^b   Vittecoq, Olivier ^b   Vilgrain, Isabelle ^a  

^a INSERM   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; GENISTEIN; ILOMASTAT; MATRIX METALLOPROTEINASE; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; ARTICLE; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; FOLLOW UP; GENE SILENCING; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ADULT; AGED; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CADHERINS; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SRC-FAMILY KINASES; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855274887     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33336     Document Type: Article

References (42)

1. Guillemin F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005; 64: 1427-30. (Pubitemid 41623852)
2. Mariette X, Gottenberg JE, Ravaud P, Combe B,. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50: 222-9.
3. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
4. Kramer HR, Giles JT,. Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity. Arthritis Care Res (Hoboken) 2011; 63: 484-99.
5. Smolen JS, Steiner G,. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-88. (Pubitemid 37361728)
6. Vestweber D, Winderlich M, Cagna G, Nottebaum AF,. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 2009; 19: 8-15.
7. Wallez Y, Vilgrain I, Huber P,. Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 2006; 16: 55-9. (Pubitemid 43214527)
8. Angelini DJ, Hyun SW, Grigoryev DN, Garg P, Gong P, Singh IS, et al. TNF-α increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia. Am J Physiol Lung Cell Mol Physiol 2006; 291: L1232-45. (Pubitemid 44904530)
9. Wallez Y, Huber P,. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta 2008; 1778: 794-809. (Pubitemid 351317803)
10. Shasby DM, Ries DR, Shasby SS, Winter MC,. Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin. Am J Physiol Lung Cell Mol Physiol 2002; 282: L1330-8. (Pubitemid 34654590)
11. Hermant B, Bibert S, Concord E, Dublet B, Weidenhaupt M, Vernet T, et al. Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. J Biol Chem 2003; 278: 14002-12. (Pubitemid 36799944)
12. Hudry-Clergeon H, Stengel D, Ninio E, Vilgrain I,. Platelet-activating factor increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3′-kinase. FASEB J 2005; 19: 512-20. (Pubitemid 40471242)
13. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 2002; 100: 1334-9. (Pubitemid 34864289)
14. Herren B, Levkau B, Raines EW, Ross R,. Cleavage of β-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 1998; 9: 1589-601. (Pubitemid 28303499)
15. Lynch CC, Matrisian LM,. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70: 561-73. (Pubitemid 36194320)
16. Wu WB, Huang TF,. Activation of MMP-2, cleavage of matrix proteins, and adherens junctions during a snake venom metalloproteinase-induced endothelial cell apoptosis. Exp Cell Res 2003; 288: 143-57.
17. Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P, et al. ADAM10 regulates endothelial permeability and T-cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res 2008; 102: 1192-201.
18. Garnier-Raveaud S, Usson Y, Cand F, Robert-Nicoud M, Verdetti J, Faury G,. Identification of membrane calcium channels essential for cytoplasmic and nuclear calcium elevations induced by vascular endothelial growth factor in human endothelial cells. Growth Factors 2001; 19: 35-48. (Pubitemid 32970679)
19. Goeb V, Dieude P, Daveau R, Thomas-L'Otellier M, Jouen F, Hau F, et al. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis. Rheumatology (Oxford) 2008; 47: 1208-12. (Pubitemid 352038228)
20. Goeb V, Dieude P, Vittecoq O, Mejjad O, Menard JF, Thomas M, et al. Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1056-62.
21. Lambeng N, Wallez Y, Rampon C, Cand F, Christe G, Gulino-Debrac D, et al. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. Circ Res 2005; 96: 384-91. (Pubitemid 40279914)
22. Potter MD, Barbero S, Cheresh DA,. Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and β-catenin and maintains the cellular mesenchymal state. J Biol Chem 2005; 280: 31906-12. (Pubitemid 41291941)
23. Allingham MJ, van Buul JD, Burridge K,. ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. J Immunol 2007; 179: 4053-64.
24. Nottebaum AF, Cagna G, Winderlich M, Gamp AC, Linnepe R, Polaschegg C, et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J Exp Med 2008; 205: 2929-45.
25. Martel-Pelletier J, Welsch DJ, Pelletier JP,. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 2001; 15: 805-29. (Pubitemid 34092514)
26. Merlos-Suarez A, Ruiz-Paz S, Baselga J, Arribas J,. Metalloprotease- dependent protransforming growth factor-α ectodomain shedding in the absence of tumor necrosis factor-α-converting enzyme. J Biol Chem 2001; 276: 48510-7.
27. Visse R, Nagase H,. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39. (Pubitemid 36542523)
28. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20. (Pubitemid 20360757)
29. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65. (Pubitemid 34084631)
30. Blobel CP,. Remarkable roles of proteolysis on and beyond the cell surface. Curr Opin Cell Biol 2000; 12: 606-12.
31. Feldmann M, Maini RN,. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 2010; 185: 791-4.
32. Zhao Y, Davis HW,. Hydrogen peroxide-induced cytoskeletal rearrangement in cultured pulmonary endothelial cells. J Cell Physiol 1998; 174: 370-9. (Pubitemid 28068714)
33. Massague J, Pandiella A,. Membrane-anchored growth factors. Annu Rev Biochem 1993; 62: 515-41. (Pubitemid 23237880)
34. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999; 58: 691-7. (Pubitemid 29517255)
35. Ichikawa Y, Ishikawa T, Momiyama N, Kamiyama M, Sakurada H, Matsuyama R, et al. Matrilysin (MMP-7) degrades VE-cadherin and accelerates accumulation of β-catenin in the nucleus of human umbilical vein endothelial cells. Oncol Rep 2006; 15: 311-5.
36. Luplertlop N, Misse D, Bray D, Deleuze V, Gonzalez JP, Leardkamolkarn V, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep 2006; 7: 1176-81. (Pubitemid 44660576)
37. Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP,. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 2009; 29: 2694-703.
38. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N,. Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J 2004; 68: 1-5. (Pubitemid 38139928)
39. Navaratna D, McGuire PG, Menicucci G, Das A,. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007; 56: 2380-7. (Pubitemid 47358245)
40. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11. (Pubitemid 38608061)
41. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81. (Pubitemid 38296553)
42. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43. (Pubitemid 39488667)